ANAB
Price
$22.56
Change
+$1.95 (+9.46%)
Updated
Sep 3, 04:59 PM (EDT)
Capitalization
631.07M
68 days until earnings call
ENTA
Price
$8.82
Change
-$0.18 (-2.00%)
Updated
Sep 3 closing price
Capitalization
189.19M
74 days until earnings call
Interact to see
Advertisement

ANAB vs ENTA

Header iconANAB vs ENTA Comparison
Open Charts ANAB vs ENTABanner chart's image
AnaptysBio
Price$22.56
Change+$1.95 (+9.46%)
Volume$12.29K
Capitalization631.07M
Enanta Pharmaceuticals
Price$8.82
Change-$0.18 (-2.00%)
Volume$220.98K
Capitalization189.19M
ANAB vs ENTA Comparison Chart in %
Loading...
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANAB vs. ENTA commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Buy and ENTA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ANAB: $20.61 vs. ENTA: $9.00)
Brand notoriety: ANAB and ENTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANAB: 39% vs. ENTA: 244%
Market capitalization -- ANAB: $631.07M vs. ENTA: $189.19M
ANAB [@Biotechnology] is valued at $631.07M. ENTA’s [@Biotechnology] market capitalization is $189.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANAB’s FA Score shows that 0 FA rating(s) are green whileENTA’s FA Score has 1 green FA rating(s).

  • ANAB’s FA Score: 0 green, 5 red.
  • ENTA’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTA is a better buy in the long-term than ANAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANAB’s TA Score shows that 7 TA indicator(s) are bullish while ENTA’s TA Score has 7 bullish TA indicator(s).

  • ANAB’s TA Score: 7 bullish, 3 bearish.
  • ENTA’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, ANAB is a better buy in the short-term than ENTA.

Price Growth

ANAB (@Biotechnology) experienced а +3.26% price change this week, while ENTA (@Biotechnology) price change was +4.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

ANAB is expected to report earnings on Nov 11, 2025.

ENTA is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANAB($631M) has a higher market cap than ENTA($189M). ENTA (56.522) and ANAB (55.665) have similar YTD gains . ANAB has higher annual earnings (EBITDA): -59.63M vs. ENTA (-82.41M). ANAB has more cash in the bank: 266M vs. ENTA (204M). ANAB has less debt than ENTA: ANAB (15.1M) vs ENTA (58M). ANAB has higher revenues than ENTA: ANAB (123M) vs ENTA (64.8M).
ANABENTAANAB / ENTA
Capitalization631M189M334%
EBITDA-59.63M-82.41M72%
Gain YTD55.66556.52298%
P/E RatioN/AN/A-
Revenue123M64.8M190%
Total Cash266M204M130%
Total Debt15.1M58M26%
FUNDAMENTALS RATINGS
ANAB vs ENTA: Fundamental Ratings
ANAB
ENTA
OUTLOOK RATING
1..100
1279
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6446
P/E GROWTH RATING
1..100
751
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ANAB's Valuation (85) in the Biotechnology industry is in the same range as ENTA (95). This means that ANAB’s stock grew similarly to ENTA’s over the last 12 months.

ANAB's Profit vs Risk Rating (90) in the Biotechnology industry is in the same range as ENTA (100). This means that ANAB’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's SMR Rating (98) in the Biotechnology industry is in the same range as ANAB (100). This means that ENTA’s stock grew similarly to ANAB’s over the last 12 months.

ENTA's Price Growth Rating (46) in the Biotechnology industry is in the same range as ANAB (64). This means that ENTA’s stock grew similarly to ANAB’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ANAB (75). This means that ENTA’s stock grew significantly faster than ANAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANABENTA
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 15 days ago
71%
Declines
ODDS (%)
Bearish Trend 9 days ago
82%
Bearish Trend 8 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
73%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TGLDF0.10N/A
+3.64%
RENEGADE GOLD INC.
IVEVF2.28N/A
N/A
INVENTIVA SA
RDBBF0.23N/A
N/A
ARTICORE GROUP LTD.
SDZNY61.47-1.42
-2.26%
Sandoz Group AG
PSMMY28.09-0.84
-2.90%
Persimmon Plc

ANAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with QTTB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANAB
1D Price
Change %
ANAB100%
+1.38%
QTTB - ANAB
40%
Loosely correlated
N/A
SPRY - ANAB
38%
Loosely correlated
-4.30%
ADCT - ANAB
38%
Loosely correlated
+0.98%
HRMY - ANAB
36%
Loosely correlated
+0.57%
CLRB - ANAB
36%
Loosely correlated
-1.03%
More

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with BEAM. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+7.14%
BEAM - ENTA
36%
Loosely correlated
-0.31%
ADCT - ENTA
35%
Loosely correlated
+0.98%
ANAB - ENTA
34%
Loosely correlated
+1.38%
FATE - ENTA
34%
Loosely correlated
-0.96%
AKRO - ENTA
34%
Loosely correlated
-2.76%
More